U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07283159) titled 'Tenecteplase Plus Urinary Kallidinogenase for Acute Ischemic Stroke (TUKIS)' on Dec. 02.
Brief Summary: Human urinary kallidinogenase (HUK) is a tissue kallikrein extracted from human urine. Under certain conditions, tissue kallikrein can convert kininogen into kallidin and kinins, thereby promoting vascular endothelial function, and exerting anti-inflammatory and antioxidant effects. Preclinical and clinical studies have demonstrated that HUK can salvage the ischemic penumbra and significantly promote the establishment of collateral circulation. Existing research suggests that the combination of HUK with intravenous alteplase signi...